Namwiwat Medical vs Baxter International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Namwiwat Medical (NAM.BK)

Q3 202621 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

August 202621 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

Latest21 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

Baxter International Inc (BAX)

Q3 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

August 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

Latest29 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.